As filed with the Securities and Exchange Commission on August 7, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Atea Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
| Delaware |
|
46-0574869 |
| (State or other jurisdiction of
Incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
225 Franklin Street, Suite 2100
Boston, MA 02110
Telephone: (857) 284-8891
(Address of principal executive offices) (Zip code)
Atea Pharmaceuticals, Inc. 2020 Incentive Award Plan
Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan
(Full title of the plan)
Jean-Pierre Sommadossi, Ph.D.
President and Chief Executive Officer
Atea Pharmaceuticals, Inc.
225 Franklin Street, Suite 2100
Boston, MA 02110
Telephone: (857) 284-8891
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
With copies to:
Peter Handrinos
Jenna
Cooper
Latham & Watkins LLP
200 Clarendon Street
Boston, MA 02116
(617) 948-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
| Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
| Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
